Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

$21.93 Bn Colorectal Cancer Drugs Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F

globenewswire.com
MRK Merck & Co. is mentioned as a major player in the colorectal cancer drugs market with an 11.38% share, indicating its significant presence in this sector. AMGN Amgen Inc. is identified as a key competitor in the colorectal cancer drugs market, holding an 8.74% market share, suggesting its substantial role. BMY LLY TAK Takeda Pharmaceutical Company is listed as a key competitor in the colorectal cancer drugs market, indicating its role and participation. PFE Pfizer Inc. is named as a key competitor in the colorectal cancer drugs market, highlighting its position and involvement in the industry. SNY Sanofi is identified as a key competitor in the colorectal cancer drugs market, indicating its presence and relevance in the sector.

Dublin, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The "Colorectal Cancer Drugs Global Market Opportunities and Strategies to 2034" has been added to ResearchAndMarkets.com's offering.

The report provides an in-depth analysis of the colorectal cancer drugs market, covering the periods from 2019-2024 as the historic period, and projecting forward from 2024-2029 and to 2034. It evaluates the market across different regions and major economies. In 2024, the global market reached $12.95 billion, reflecting a CAGR of 6.74% since 2019. Looking ahead, it is anticipated to grow to $16.88 billion by 2029 at a CAGR of 5.45%, eventually reaching $21.93 billion by 2034 with a CAGR of 5.37% from 2029.

Growth during the historic period was driven by factors such as increased clinical trials, higher incidence of colorectal cancer, supportive government initiatives, and advancements in precision medicine and targeted therapies. Challenges included high treatment costs, affordability issues, and the severe side effects of chemotherapy and biologics. Moving forward, growth will be propelled by factors like enhanced awareness and screening programs, increased healthcare spending, wider adoption of combination therapies, and a rising aging population. However, potential obstacles include reimbursement challenges, stringent regulatory approvals, and the impact of global trade tensions.

North America had the largest share in the colorectal cancer drugs market in 2024, accounting for 43.68% or $5.65 billion. It was followed by Asia Pacific, Western Europe, among other regions. The fastest growth rates in the future are expected in Asia Pacific and the Middle East with CAGRs of 6.75% and 6.34%, respectively, followed by Africa and Eastern Europe.

The market is concentrated, with the top ten competitors accounting for 47.10% of the total market in 2024. Major players include Merck & Co. Inc with an 11.38% share, Amgen Inc at 8.74%, and Bristol-Myers Squibb at 7.39%. Other key competitors are F. Hoffmann-La Roche Ltd, Eli Lilly & Company, Bayer AG, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, and Taiho Pharmaceutical.

Market segmentation by cancer type includes colorectal adenocarcinoma, gastrointestinal carcinoid tumors, among others. Colorectal adenocarcinoma dominated with a 92.48% share in 2024. The gastrointestinal carcinoid tumors segment is expected to see the fastest growth at a CAGR of 10.29% from 2024-2029. By class, the market segments include targeted therapies, immunotherapies, and chemotherapy, with chemotherapy being the largest segment at 45.60% in 2024. The immunotherapy segment is anticipated to grow rapidly at a CAGR of 8.10%. By distribution channel, hospital pharmacies led with 50.27% in 2024, and retail pharmacies are expected to grow the fastest at a CAGR of 6.29%.

The colorectal adenocarcinoma segment is projected to offer the greatest opportunities, with potential sales increasing by $3.57 billion globally by 2029. Targeted therapy and hospital pharmacies present significant market opportunities, anticipating gains of $1.43 billion and $1.76 billion respectively by 2029. The U.S. is predicted to experience the most considerable market size increase, at $1.43 billion.

Market strategies focus on biosimilar innovations to enhance accessibility and reduce costs, advancement in the treatment of BRAF V600E-Mutant metastatic colorectal cancer, and combining EGFR inhibitors with KRAS G12C-targeted agents to address resistance. Strategic approaches adopted by companies include launching new drugs, forming partnerships, and making investments to strengthen operational capabilities. Companies are advised to expand biosimilar portfolios, advance targeted therapies, focus on combination regimens, enhance digital promotional channels, and expand into emerging markets to seize growth opportunities.

Key Attributes:

Chapters Covered:

Markets and Segments:

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/ea4a29

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment